FDNA BIOTECH
Founded by Dekel Gelbman, FDNA aids clinicians, researchers, and genetic testing labs worldwide in finding answers and treatments for patients living with a genetic disease. Face2Gene is a suite of phenotyping applications that facilitate comprehensive and precise genetic evaluations. Essentially it is a diagnosis using a phone camera. FDNA’s database includes phenotypic and genotypic information associated with more than 10,000 diseases from real-world patient cases. This de-identified data is collected and stored in a private and secure cloud-based clinical warehouse and integrated to LIMS (Laboratory Information Management System), EMR (Electronic Medical Records) and variant interpretation systems through a set of open APIs (Application Programming Interfaces).
Using the most advanced deep learning and artificial intelligence technologies, FDNA has created next-generation phenotyping (NGP), technologies that capture, structure, and analyze complex human physiological data to produce actionable genomic insights from next-generation sequencing (NGS) data.
NGP improves the diagnostic efficiency in the NGS analysis in that it enables and provides essential support for clinical correlation. The Prioritization of Exome Data Image Analysis (PEDIA)2 study found that the causative variant is ranked within the top-10 variants in more than 90% of cases when NGP and genomic scores are combined.
Dekel Gelbman, founder and CEO of FDNA, leads the corporate and business strategy of an innovative digital health company that develops technologies and SaaS platforms used by thousands of clinical, research and lab sites globally in the clinical genomics space. Before FDNA, Mr. Gelbman was a practicing corporate and transactional attorney working for leading law firms, including among others, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates. Mr. Gelbman’s experience includes working closely with a variety of technology and biotech companies, at all stages – from startups through growth stage companies and to mature, publicly-traded companies. Mr. Gelbman holds an LL. B and an MBA in finance.
FDNA has ceased operations. Those interested can contact Dekel Gelbman at dekelgelbman@gmail.com
http://linkedin.com/in/dekelgelbman
2 Hsieh TC, Mensah MA, […] Krawitz PM (2019) PEDIA: prioritization of exome data by image analysis. Genetics in Medicine. N= 679 retrospective patients diagnosed with monogenic disorders